|Study Description:||The goal of this clinical research study is to learn if a combination of |
trametinib and GSK2141795 can help to control AML. The highest tolerable dose
level as well as the safety of the drugs will also be studied.
Trametinib is designed to block MEK proteins, and GSK2141795 is designed to
block AKT proteins. These proteins cause cancer cells to grow and multiply.
Blocking these proteins may possibly cause the cancer cells to die.
The combination of trametinib and GSK2141795 being used to treat AML with RAS
mutations is considered experimental.